Cancer researchers testing radical change in drug trials

UC San Francisco's Laura Esserman is taking a leading role in I-Spy 2, an innovative cancer trial that will rotate through up to 12 experimental cancer therapies in an effort to determine if a radical new approach can identify the right population for the right therapy on a much smaller budget.

Esserman and co-leader Don Berry at M.D. Anderson Cancer Center are currently using an adaptive trial design to screen the efficacy of five breast cancer drugs from three different companies--Abbott, Amgen and Pfizer--according to an in-depth feature in the Wall Street Journal. MRIs are used to track tumor response with surgery providing hard evidence of success or failure. "All of a sudden I've taken a five-year learning curve and shortened it to six months," Dr. Esserman tells the WSJ.

Esserman and Berry are out to execute a "knowledge turn," looking for a key technological breakthrough that can radically improve a difficult process. That's particularly needed in late-stage cancer tests, which often end in failure after racking up massive costs.

"The vision is a 300-patient phase III trial instead of a 3,000-patient trial, with better results," Berry tells the Journal. As one drug fails the process, researchers can add another in hopes of identifying winners at an early stage.

- here's the WSJ article

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.